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Abstract
Central giant cell lesions are benign intraosseous proliferative lesions that have considerable local aggressiveness.
Nonsurgical treatment methods, such as intralesional corticosteroid injections, systemic calcitonin and interferon
have been reported. Recently, bisphosphonates have been used to treat central giant cell lesions. A case of a
36-year-old male with a central giant cell lesion crossing the mandibular midline was treated with intralesional
corticosteroids combined with alendronate sodium for the control of systemic bone resorption. The steroid
injections and the use of bisphosphonates were stopped after seven months when further needle penetration into
the lesion was not possible due to new bone formation. After two years, the bony architecture was near normal,
and only minimal radiolucency was present around the root apices of the involved teeth. The patient was followed
up for four years, and panoramic radiography showed areas of new bone formation. Thus far, neither recurrence
nor side effects of the medication have been detected.
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Background
Central giant cell lesions (CGCLs) are benign intraosseous
proliferative lesions that occur in the maxilla and mandible
primarily during the first to third decades of life [1]. Histo-
logically, multinucleated giant cells are prominent through-
out the fibroblastic stroma and are often clustered around
areas of haemorrhage [2].
CGCLs represent a treatment challenge. The clinical
behaviour is extremely variable in that certain lesions
are completely silent and grow very slowly whereas
others behave more aggressively [3]. In recurrent or ag-
gressive lesions, en bloc resection is a treatment option,
but this procedure results in large surgical defects [4,5].
Nonsurgical treatment methods, such as intralesional
corticosteroid injections and systemic calcitonin or inter-
feron-α, are increasingly being used [4,6-11].
Steroids appear to inhibit the production of extracellu-
lar lysosomal proteases in multinucleated giant cells. In
addition, steroids reduce bone resorption and induce the
apoptosis of osteoclastic cells [5].
Bisphosphonates are widely used to inhibit osteolysis in
conditions such as osteoporosis, Paget’s disease and bone
destruction through metastatic cancer. Landesberg et al.
[1] reported three cases of CGCLs treated with bispho-
sphonates. The first case showed the successful treatment
with a single administration of intravenous bisphospho-
nates, the second resulted in a 30% reduction of the lesion,
and the last case showed stabilisation but no regression of
the lesion.
Based on such evidence, the purpose of this study was
to report a case of CGCL that had been treated with
intralesional corticosteroids and oral bisphosphonates.
Report of a case
A 36-year-old male with no relevant medical history was
referred for the evaluation of swelling on the left side of
his jaw, which had been associated with paraesthesia for
the previous 5 months. On extra-oral examination, a
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slight swelling in the chin region was noted. Intraorally,
the examination revealed swelling of the mouth vestibule
and high tooth mobility.
Panoramic radiographs showed a multilocular radio-
lucent area in the anterior mandible extending from tooth
36 to tooth 45, causing the resorption of certain teeth (Fig-
ure 1). A computed tomography (CT) scan showed that
the lesion crossed the midline and extended to the inferior
border of the mandible. In addition, there was an expan-
sion of the buccal and lingual cortices with consequent dis-
ruption. The mandibular canal on both sides and the
mandibular foramen on the left side were compromised
(Figure 2).
An incisional biopsy was performed, which showed mul-
tinucleated giant cells surrounded by a disorganised stroma
with intense inflammatory infiltrates. There were mainly
mononuclear infiltrates with numerous haemorrhagic areas
and viable bone tissue surrounding the lesion. Based on
these characteristics, the final diagnosis was CGCL
(Figure 3).
The results of blood tests were normal, and after ruling
out the possibility of the injury being associated with
hormonal disorders (hyperparathyroidism), the proposed
treatment was intralesional infiltration of triamcinolone,
similar to the protocol described by Terry and Jacoway
[12]. Such infiltrations are typically recommended to be
performed weekly for six weeks at multiple sites of the le-
sion [5,6,9].
In this case, a 1 ml ampoule of Theracort (triamcino-
lone acetonide, 40 mg/ml) diluted in 3,6 ml of 2% mepi-
vacaine (epinephrine 1:100,000) was used. The patient
received 10 injections, seven of which were given over a
period of approximately 15 days and the remaining three
injections over the course of one month. The cortico-
steroid solution was more concentrated in a specific area
of the lesion in each infiltration. After the first injection,
the anaesthetic solution was replaced by 3% mepivacaine
(without epinephrine) because the patient was tachycar-
dic during infiltration even when the procedure was per-
formed slowly for approximately five minutes.
Alendronate sodium (70 mg) was used on a weekly basis
to control bone resorption during treatment. Additionally,
oral calcium carbonate (500 mg) was administered daily to
facilitate the calcification of the lesion. The treatment
Figure 1 A Panoramic radiography. A multilocular radiolucent area crossing the midline and causing resorption in certain teeth.
Figure 2 Computed tompography scan. The expansion of the buccal and lingual cortices with consequent disruption.
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lasted seven months, after which further needle penetra-
tion into the lesion was not possible due to new bone for-
mation. The administration of alendronate sodium and
calcium carbonate was suspended at the same time.
After two years, the bony architecture was near nor-
mal and only minimal radiolucency was present around
the root apices of the involved teeth. Both the cortical
and the drilling areas proved to be repaired (Figure 4).
The patient has been followed up for four years, and he
is asymptomatic. The panoramic radiography and CT
scan showed areas of bone formation with more intense
radiopacity and no recurrence thus far (Figure 5).
Discussion
CGCLs account for 10% of all benign jaw lesions. The
proportion of mandibular to maxillary involvement is
2:1 or 3:1 [13]. Lesions are more common in the anterior
region of the jaw, and mandibular lesions frequently ex-
tend across the midline [14], as observed in our case.
Based on clinical and radiographic features, these lesions
can be classified as non-aggressive and aggressive. The
non-aggressive form is characterised by slow growth, typic-
ally asymptomatic growth that does not perforate the cor-
tical bone or induce root resorption and has a low
recurrence rate. Aggressive lesions are characterised by
Figure 3 Histological sections stained with H.E. The presence of multinucleated giant cells surrounded by a disorganised stroma with an
intense inflammatory infiltrate.
Figure 4 Follow-up after two years. The bony architecture was near normal, and only minimal radiolucency was present around the root
apices of the involved teeth.
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pain, rapid growth, paraesthesia, root resorption, cortical
perforation and a high recurrence rate after surgical treat-
ment [5]. Although the patient did not report pain, other
features of an aggressive lesion were observed, including
paraesthesia, cortical perforation and root resorption.
A number of alternative nonsurgical therapies, such as
intralesional corticosteroid injection, have been described
for the management of CGCL. On reviewing the literature,
we have found 18 reported cases that were treated with
corticosteroids, with variable responses (Table 1). In the
majority of the cases, six injections were administered, and
the patients were followed up with periodic radiographic
examination.
Steroid therapy was chosen in this case report because of
the following advantages: ease of administration and lower
invasiveness; relatively short duration of treatment (6 weeks
average compared with 3–27 months for calcitonin and
interferon-α); a relatively higher success rate compared
with calcitonin/interferon-α; cost-effectiveness; availability;
and minimal systemic side effects [10]. In addition, intrale-
sional injection is preferable to systemic administration to
achieve an elevated concentration of the medication in the
tissue [7].
CGCL treatment is described as surgery, but the evi-
dence of osteoclastic features enabled a change in the treat-
ment of more aggressive cases, which tend to recur, or the
Figure 5 Follow-up after four years. Areas of new bone formation with more intense radiopacity.
Table 1 Reported cases managed by intralesional corticosteroids injection
Year Author No. of cases Site No. of injections Time of resolution
1994 Terry and Jacoway [12] 4 Mandible 6 3 years
Mandible 6 1 year 4 months
Mandible 6 2 years 2 months
Mandible 6 Incomplete
1994 Kermer et al. [20] 1 Mandible 6 3 years
2000 Khafif et al. [21] 1 Maxilla 6 2 years
2001 Kurtz et al.[6] 1 Mandible 12 2 years
2001 Adornato and Paticoff [7] 1 Mandible 6 Partial 7 months
2002 Carlos and Sedano [8] 4 Maxilla 20 7 years
Mandible 17 6 years
Maxilla 4 Residual lesion
1 year 3 months
Mandible 4 2 years
2005 Sezer et al. [9] 1 Mandible 6 3 years
2005 Abdo et al. [18] 1 Mandible 3 1 ½ year
2009 Mohanty and Jhamb [10] 2 Mandible 5 1 ½ year
Mandible 6 1 ½ year
2010 Shirani et al. [19] 1 Mandible and maxilla 6 2 years
2011 Rachmiel et al. [11] 1 Mandible 6 5 years
Total 11 18 Proportion mandible:maxilla 15:4 Mean 7.27 Mean 2 ½ years
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cases with extensive destruction that require reconstructive
surgery. In this case, the patient did not undergo surgery
because he wished to preserve the nearby teeth and their
vitality, to avoid endodontic treatments, and to preserve
the maintenance of periodontal support and the structure
of the adjacent bone.
It is well known that corticosteroids decrease blood cal-
cium levels by suppressing intestinal calcium absorption
and decreasing vitamin D activity and the reabsorption of
calcium in the renal tubules [15]. In the present case, cal-
cium carbonate was administered to facilitate the calcifica-
tion of the lesion.
Bisphosphonates inhibit the formation of osteoclasts
from immature precursor cells and induce the apoptosis of
mature osteoclasts. Landesberg et al. [1] reported three
cases of CGCLs treated with bisphosphonates with variable
responses. It is evident in the two cases that the most sig-
nificant regression is observed after the initial infusion of
the drug. In the patient who received the drug at yearly
intervals, it is difficult to determine whether higher doses
and/or frequency of drug administration would have
shown a more favourable result. The authors suggested
that this drug might be useful as a primary or adjunctive
therapy in the treatment of CGCL.
The administration of bisphosphonates in Paget’s disease,
bone metastases of multiple myeloma, breast and prostate
cancers and osteoporosis effectively restores bone mineral
density and bone strength, reduces the incidence of bone
fracture and dramatically improves quality of life [16].
Although bisphosphonates are generally well tolerated,
bisphosphonate exposure has been linked to osteonecro-
sis of the jaw (ONJ). The most important predisposing
factors for this condition are the type and total dose of
bisphosphonate and a history of trauma, dental surgery
or dental infection. The risk is substantially higher for
patients taking zoledronic acid and increases over time,
likely because of the long half-life of these drugs. The
degree of risk for ONJ in patients taking oral bispho-
sphonates, such as alendronate, for osteoporosis is un-
certain and warrants careful monitoring [17].
The combination of steroids with bisphosphonates
appears to be valid because the former have been widely
used in the treatment of CGCL [4,9-11,18-20], whereas the
latter have been used successfully in antiresorptive bone
lesions, such as osteoporosis and Paget’s diseases [1]. Al-
though bisphosphonates have been successfully used to
control bone resorption in various diseases [1,16].
Various possibilities of treatment or drug control
increased the challenge of elucidating biomolecular char-
acteristics at the time of diagnosis. We must not forget
the possibility of changes that may occur with these
developments, which emphasise the importance of bio-
molecular analysis [5]. It is also important to remember
that these treatments until then described the main
targets for the control of osteoclastogenesis, which is
likely the expression of a genetic mutation or a meta-
bolic disturbance. Therefore, research should continue
to identify the factor that stimulates this local osteoclas-
togenesis and determine the most effective treatment.
Conclusion
The treatment for CGCLs remains controversial because
recurrence is possible. Although the surgical procedures
are effective, they have poor aesthetic and functional
results when large resections are performed. Unfortu-
nately, in this study, the combination of alendronate
with corticosteroids does not appear to have benefits in
treating CGCL; however, only clinical trials with a large
sample size will confirm the advantages of this
association.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and any accom-
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able for review by the Editor-in-Chief of this journal.
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